He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a published ...

While there are plenty of things to worry about these days, the ability of AI to weaponize biology into one of the largest ...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients ...

The merger will be carried out by means of an absorption merger. Veraxa Biotech Holding AG, as the acquiring company, will take over VERAXA as the transferring company and simultaneously change its ...

A new machine learning tool hints at the breath of bogus papers in cancer research and reveals how attractive this research ...

ParaZero Technologies Ltd. (Nasdaq: PRZO) (the 'company” or 'ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) ...

VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ('Aptorum Group” or ...

There is something about Ramadan that slows the rhythm of life just enough to make you notice what you would otherwise rush past. The days are structured around restraint, the nights around reflection ...

Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with ...

The next phase of AI, already underway, will integrate text with vision, sound, motion and even touch. This will produce systems that no longer 'read about' the world but perceive it.